(5-bromopyridin-2-yl)-(2-methoxyethyl)methylamine | 214831-64-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (5-bromopyridin-2-yl)-(2-methoxyethyl)methylamine
• 英文别名: 5-bromo-N-(2-methoxyethyl)-N-methylpyridin-2-amine
• CAS: 214831-64-8
• 化学式: C₉H₁₃BrN₂O
• mdl: MFCD14664848
• 分子量: 245.119
• InChiKey: CDKDPQWKJKDJCB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.444
• 拓扑面积：
  25.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (5-bromopyridin-2-yl)-(2-methoxyethyl)methylamine 在 bis-triphenylphosphine-palladium(II) chloride 哌啶 、 copper(l) iodide 、 potassium carbonate 作用下， 以 甲醇 为溶剂， 反应 24.0h， 生成 (5-ethynylpyridin-2-yl)(2-methoxyethyl)methylamine
  参考文献：
  名称：

  4-Amino-5-aryl-6-arylethynylpyrimidines: Structure–activity relationships of non-nucleoside adenosine kinase inhibitors

  摘要：

  A series of non-nucleoside adenosine kinase (AK) inhibitors is reported. These inhibitors originated from the modification of 5-(3-bromophenyl)-7-(6-morpholin-4-ylpyridin-3-yl)pyrido[2,3-d]pyrimidin-4-ylamine (ABT-702). The identification of a linker that would approximate the spatial arrangement found between the pyrimidine ring and the aryl group at C(7) in ABT702 was a key element in this modification. A search of potential linkers led to the discovery of an acetylene moiety as a suitable scaffold. It was hypothesized that the aryl acetylenes, ABT-702, and adenosine bound to the active site of AK (closed form) in a similar manner with respect to the orientation of the heterocyclic base. Although potent acetylene analogs were discovered based on this assumption, an X-ray crystal structure of 5-(4-dimethylaminophenyl)-6-(6-morpholin-4-yipyridin-3-ylethynyl)pyrimidin-4-ylamine (16a) revealed a binding orientation contrary to adenosine. In addition, this compound bound tightly to a unique open conformation of AK. The structure-activity relationships and unique ligand orientation and protein conformation are discussed. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.12.029
• 作为产物：
  描述：

  2,5-二溴吡啶 、 N-(2-甲氧基乙基)甲基胺 在 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 二甲基亚砜 为溶剂， 反应 120.0h， 生成 (5-bromopyridin-2-yl)-(2-methoxyethyl)methylamine
  参考文献：
  名称：

  [EN] PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS
  [FR] COMPOSÉS DE PYRAZOLE ET LEUR UTILISATION EN TANT QUE BLOQUEURS DES CANAUX CALCIQUES DE TYPE T

  摘要：

  这项发明涉及式(I)的化合物。式(I)中X、Y、R1、R2、(R4)n和(R5)m的定义如描述中所述，并且涉及这些化合物的药用盐。这些化合物可用作钙T通道阻滞剂。

  公开号：

  WO2015186056A1

文献信息

• [EN] APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE KINASE DE RÉGULATION DU SIGNAL DE L'APOPTOSE ET LEURS UTILISATIONS
  申请人：FRONTHERA U S PHARMACEUTICALS LLC

  公开号：WO2019051265A1

  公开（公告）日：2019-03-14

  Described herein are ASK1 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of blood disease, autoimmune disorders, pulmonary disorders, hypertension, inflammatory diseases, fibrotic diseases, diabetes, diabetic nephropathy, renal diseases, respiratory diseases, cardiovascular diseases, acute lung injuries, acute or chronic liver diseases, and neurodegenerative diseases.

  本文描述了ASK1抑制剂和包含该化合物的药物组合物。所述化合物和组合物对于治疗血液疾病、自身免疫性疾病、肺部疾病、高血压、炎症性疾病、纤维化疾病、糖尿病、糖尿病肾病、肾脏疾病、呼吸系统疾病、心血管疾病、急性肺损伤、急性或慢性肝病以及神经退行性疾病具有用处。
• Pyrazole compounds and their use as T-type calcium channel blockers
  申请人：IDORSIA PHARMACEUTICALS LTD

  公开号：US10065929B2

  公开（公告）日：2018-09-04

  The invention relates to compounds of formula (I) wherein X, Y, R1, R2, (R4)n, and (R5)m are as defined in the description, and to pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium T-channel blockers.

  本发明涉及式 (I) 的化合物 其中X、Y、R1、R2、(R4)n和(R5)m如描述中所定义，并涉及此类化合物的药学上可接受的盐。这些化合物可用作钙 T 通道阻滞剂。
• 3-CYANOQUINOLINES,3-CYANO-1,6-NAPHTHYRIDINES, AND 3-CYANO-1,7-NAPHTHYRIDINES AS PROTEIN KINASE INHIBITORS
  申请人：Wyeth

  公开号：EP1268431B1

  公开（公告）日：2007-08-29
• Respiratory syncytial virus replication inhibitors
  申请人：JANSSEN PHARMACEUTICA N.V.

  公开号：EP1400519B1

  公开（公告）日：2007-03-07
• PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS
  申请人：Actelion Pharmaceuticals Ltd.

  公开号：EP3152199A1

  公开（公告）日：2017-04-12